On April 1 st, 2025, TuHURA Biosciences, Inc. (NASDAQ:HURA) reported 2024 financial and operational results and filed its Form 10-K with the SEC. TuHURA provided updates on its Phase III trial in ...

We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation of $9.25 per share. This value is based on our estimates for successful development and commercialization of ...

In this article, we are going to take a look at where TuHURA Biosciences, Inc. (NASDAQ:HURA) stands against other best rising penny stocks to buy according to analysts. The start of 2025 was ...

Financially, HURA's cash burn rate suggests a need for additional funding, despite recent financing that extends cash runway into late 2025. Overall, HURA's high-risk profile and early-stage ...